Information about ensuring blood and blood component safety.
Similar Posts
Class 4 Medicines Defect Notification: Olmesartan medoxomil 10mg film-coated tablets, Jubilant Pharmaceuticals NV, EL(25)A/37
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient Information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2024-25
MHRA transactions over £500 made using the government procurement card (GPC).
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks
Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They also include previous updates to product information on the risk of low birth weight in children exposed to valproate during pregnancy.
MHRA’s 2024–25 Annual Report and Accounts and Impact Report show progress on safety, innovation, and regulatory excellence
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Accounts, and accompanying Impact Report.
Guidance: MMRV Vaccine Factsheet – Information for Parents and Caregivers
The MMRV vaccine will become part of the routine childhood immunisation schedule in the UK from 1 January 2026.
COVID-19 test approval: how to apply
How manufacturers or distributors of Coronavirus (COVID-19) test devices can apply for approval of their tests to be placed on the UK market.